MX2010004313A - Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso. - Google Patents

Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.

Info

Publication number
MX2010004313A
MX2010004313A MX2010004313A MX2010004313A MX2010004313A MX 2010004313 A MX2010004313 A MX 2010004313A MX 2010004313 A MX2010004313 A MX 2010004313A MX 2010004313 A MX2010004313 A MX 2010004313A MX 2010004313 A MX2010004313 A MX 2010004313A
Authority
MX
Mexico
Prior art keywords
sup
compounds
ksp kinesin
kinesin activity
inhibiting ksp
Prior art date
Application number
MX2010004313A
Other languages
English (en)
Inventor
M Arshad Siddiqui
Chaoyang Dai
Umar Faruk Mansoor
Liping Yang
Lalalnthi Dilrukshi Vitharana
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010004313A publication Critical patent/MX2010004313A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos de la formula (I) siguiente, (ver fórmula I) en donde R1, R2, R3, p, E, anillo A y anillo B son como se definen en la presente; la presente invención se refiere también a composiciones (incluyendo composiciones farmacéuticamente aceptables) que comprenden estos compuestos, solos y en combinación con uno o más agentes terapéuticos adicionales, y a métodos para su uso en la inhibición de la actividad de quinesina en la proteína de husillo de quinesina (KSP) y para tratar enfermedades proliferativas celulares o trastornos asociados con la actividad de quinesina en KSP.
MX2010004313A 2007-11-07 2008-10-16 Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso. MX2010004313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98617307P 2007-11-07 2007-11-07
PCT/US2008/080169 WO2009061595A1 (en) 2007-11-07 2008-10-16 Compounds for inhibiting ksp kinesin activity

Publications (1)

Publication Number Publication Date
MX2010004313A true MX2010004313A (es) 2010-07-06

Family

ID=40219992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004313A MX2010004313A (es) 2007-11-07 2008-10-16 Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.

Country Status (9)

Country Link
US (1) US20110171172A1 (es)
EP (1) EP2217605A1 (es)
JP (1) JP2011502988A (es)
CN (1) CN101903395A (es)
AR (1) AR068890A1 (es)
CA (1) CA2702985A1 (es)
MX (1) MX2010004313A (es)
TW (1) TW200922573A (es)
WO (1) WO2009061595A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003063A1 (es) * 2007-10-19 2010-01-04 Schering Corp Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
WO2010132520A1 (en) * 2009-05-13 2010-11-18 Schering Corporation Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249597B2 (en) * 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CN101106998A (zh) * 2005-01-19 2008-01-16 默克公司 有丝分裂驱动蛋白抑制剂

Also Published As

Publication number Publication date
WO2009061595A1 (en) 2009-05-14
AR068890A1 (es) 2009-12-16
TW200922573A (en) 2009-06-01
CN101903395A (zh) 2010-12-01
JP2011502988A (ja) 2011-01-27
EP2217605A1 (en) 2010-08-18
US20110171172A1 (en) 2011-07-14
CA2702985A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
MX2010004312A (es) Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
HK1095139A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
HK1095138A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
HK1097189A1 (en) Cannabinoid receptor ligands
IL175714A0 (en) Quinazolinone compounds as anticancer agents
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
DE602004011394D1 (en) Thiazolderivate
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2012004848A (es) Compuestos heterociclicos triciclicos.
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
TW200611695A (en) Pyrrolopyridine derivatives
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
WO2007109251A3 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
TW200637817A (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal